SecBot SecBot

DNLI drug pipeline

Denali Therapeutics Inc. · 1 rated drug
$18.08
−3.5% 1-day · Nov 16
Next catalyst
2027
zafinofusp alfa BLA filing
Typical move on FDA news
±6.0%
1-day, median of 12 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

2 dated
  1. Dec 2026
    DNL593
    Phase 2 primary completion
  2. 2027
    zafinofusp alfa
    BLA filing · Sanfilippo syndrome type A

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (accelerated approval)
Time to marketAlready approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.

tividenofusp alfa-eknm tividenofusp alfa Updated Oct 31

What to watch

The next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.

Bull case
  • Avlayah is the first and only FDA-approved therapy designed to cross the blood-brain barrier for Hunter syndrome, addressing the neurologic manifestations that Takeda's Elaprase cannot treat, giving it a clear differentiation and potential to become standard of care.
  • The early commercial launch is exceeding expectations: Q2 2026 generated $3.6M in net product revenue (vs analyst estimates of $1.3M), and management guided Q3 2026 to $10-12M, implying rapid quarter-over-quarter growth.
  • Denali has a strong balance sheet with pro forma cash exceeding $1.1B after the $195M PRV sale, providing runway to fund its broader pipeline including DNL126 (Sanfilippo syndrome) and Alzheimer's programs through multiple catalysts.
Bear case
  • Avlayah's accelerated approval was based on a biomarker surrogate (CSF heparan sulfate) in a 47-patient open-label Phase 1/2 trial; full approval depends on the ongoing Phase 2/3 COMPASS confirmatory trial, which could fail to show clinical benefit and jeopardize the label.
  • The drug carries a list price of roughly $270,000 to over $811,000 per year depending on patient weight, which could face payer access and reimbursement headwinds in a rare disease market currently served by Takeda's Elaprase.
  • Insider selling was detected in the evidence window (CMO, directors, COFO sold shares in Aug-Sep 2026), and several institutional holders trimmed or exited positions in Q2 2026, including a near-exit by Alyeska Investment Group.

Other drugs in filings and trials

no drug report yet
  • zafinofusp alfa Next: BLA filing · 2027
  • DNL593 Last: Orphan drug designation · Aug 6, 2026 1 trial
  • DNL126 Last: NDA filed · Feb 3, 2026

Past FDA events & how the stock moved

12 events
DateDrugEvent1 day5 days
Aug 6, 2026DNL593Orphan drug designation+1.7%+1.6%
Aug 1, 2026DNL593Orphan drug designation+0.6%+7.9%
Apr 5, 2026tividenofusp alfa-eknmAccelerated approval−6.2%−6.9%
Apr 5, 2026tividenofusp alfa-eknmPriority review−6.2%−6.9%
Apr 5, 2026tividenofusp alfa-eknmPDUFA decision−6.2%−6.9%
Apr 5, 2026tividenofusp alfa-eknmBLA filed−6.2%−6.9%
Mar 25, 2026tividenofusp alfa-eknmApproval−5.9%−6.2%
Mar 25, 2026tividenofusp alfa-eknmAccelerated approval−5.9%−6.2%
Mar 24, 2026tividenofusp alfa-eknmApproval+6.5%−9.0%
Feb 3, 2026DNL126NDA filed−6.4%−12.8%
Feb 1, 2026DNL126Clinical hold+4.6%−3.0%
Feb 1, 2026DNL126Breakthrough designation+4.6%−3.0%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
DNL593A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)Phase 2Active not recruiting85Dec 2026